Knuff & Co LLC Acquires 448 Shares of DexCom, Inc. (NASDAQ:DXCM)

Knuff & Co LLC increased its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 6.6% during the third quarter, HoldingsChannel reports. The firm owned 7,245 shares of the medical device company’s stock after buying an additional 448 shares during the period. Knuff & Co LLC’s holdings in DexCom were worth $1,081,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also made changes to their positions in the company. OLD National Bancorp IN lifted its holdings in shares of DexCom by 1.1% during the second quarter. OLD National Bancorp IN now owns 9,838 shares of the medical device company’s stock valued at $1,474,000 after purchasing an additional 108 shares in the last quarter. Janney Montgomery Scott LLC lifted its holdings in shares of DexCom by 23.6% during the second quarter. Janney Montgomery Scott LLC now owns 12,360 shares of the medical device company’s stock valued at $1,852,000 after purchasing an additional 2,357 shares in the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. lifted its holdings in shares of DexCom by 14.1% during the second quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 12,320 shares of the medical device company’s stock valued at $1,846,000 after purchasing an additional 1,519 shares in the last quarter. United Capital Financial Advisers LLC lifted its holdings in shares of DexCom by 20.6% during the second quarter. United Capital Financial Advisers LLC now owns 3,161 shares of the medical device company’s stock valued at $474,000 after purchasing an additional 539 shares in the last quarter. Finally, MayTech Global Investments LLC lifted its holdings in shares of DexCom by 2.1% during the second quarter. MayTech Global Investments LLC now owns 45,365 shares of the medical device company’s stock valued at $6,797,000 after purchasing an additional 934 shares in the last quarter. 96.19% of the stock is currently owned by hedge funds and other institutional investors.

DXCM stock traded up $6.12 during trading on Monday, reaching $204.20. The stock had a trading volume of 58,247 shares, compared to its average volume of 1,138,483. DexCom, Inc. has a 52 week low of $105.05 and a 52 week high of $200.80. The stock’s 50 day moving average is $155.57 and its two-hundred day moving average is $146.29. The company has a current ratio of 6.05, a quick ratio of 5.64 and a debt-to-equity ratio of 1.56. The firm has a market cap of $14.00 billion, a PE ratio of 679.80 and a beta of 0.64.

DexCom (NASDAQ:DXCM) last posted its earnings results on Wednesday, November 6th. The medical device company reported $0.65 earnings per share for the quarter, beating analysts’ consensus estimates of $0.20 by $0.45. DexCom had a positive return on equity of 10.41% and a negative net margin of 13.96%. The company had revenue of $396.30 million for the quarter, compared to the consensus estimate of $348.99 million. During the same quarter in the prior year, the company earned $0.17 earnings per share. DexCom’s revenue was up 48.6% on a year-over-year basis. On average, research analysts anticipate that DexCom, Inc. will post 0.94 EPS for the current year.

A number of research analysts have recently issued reports on the company. JPMorgan Chase & Co. reaffirmed an “overweight” rating and set a $215.00 price target (up from $190.00) on shares of DexCom in a report on Thursday. Piper Jaffray Companies increased their target price on DexCom from $182.00 to $200.00 and gave the company an “overweight” rating in a report on Thursday. BTIG Research reissued a “hold” rating on shares of DexCom in a report on Thursday, August 1st. ValuEngine downgraded DexCom from a “buy” rating to a “hold” rating in a report on Wednesday, October 2nd. Finally, BidaskClub raised DexCom from a “hold” rating to a “buy” rating in a report on Friday, November 1st. Five equities research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $190.67.

In other DexCom news, SVP Heather S. Ace sold 7,243 shares of the company’s stock in a transaction dated Friday, August 23rd. The stock was sold at an average price of $174.80, for a total value of $1,266,076.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Nicholas Augustinos sold 1,208 shares of the company’s stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $185.29, for a total value of $223,830.32. The disclosure for this sale can be found here. In the last three months, insiders sold 105,222 shares of company stock worth $16,407,406. 1.80% of the stock is owned by corporate insiders.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.

See Also: After-Hours Trading

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM).

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.